Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 8/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 7/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469452 | 0.90 | PRMT1 (0.47) | PRMT1LRRK2 | |
| SCHEMBL17469475 | 0.88 | HTR1D (0.46) | PRMT1CARM1HTR1DTRPM8ACHE | |
| SCHEMBL17469503 | 0.88 | PRMT1 (0.46) | PRMT1LRRK2CARM1 | |
| SCHEMBL16129387 | 0.87 | FGFR4 (0.45) | PRMT1CARM1HTR1DTRPM8MAOA | |
| SCHEMBL17469493 | 0.86 | APP (0.38) | PRMT1CARM1HTR1DTRPM8MAOB | |
| SCHEMBL17469454 | 0.86 | MAOB (0.41) | PRMT1CARM1MAOAMAOB | |
| SCHEMBL16129388 | 0.86 | MAOB (0.43) | PRMT1CARM1MAOAACHEMAOB | |
| SCHEMBL17469501 | 0.85 | FLT3 (0.41) | MAOAMAOBFGFR4 | |
| SCHEMBL17469492 | 0.84 | PARP10 (0.43) | PRMT1CARM1MAOBFGFR4 | |
| SCHEMBL17469453 | 0.83 | PRMT1 (0.42) | PRMT1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885LRRK2 972/4885CARM1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.